There was no significant interaction between hs-cTnI and CHD history, or hs-cTnI and rosuvastatin treatment, for all outcomes, and Pint values for the hs-cTnI and BNP interaction indicate a weak or no significant modification of the relationship between hs-cTnI and outcomes (Supplementary Fig. 4A–D). Here, TNNI3 is linked to coronary artery disorder.